Neurogene Inc. reported second quarter 2026 financial results on August 11, 2026, announcing a net loss of $34.5 million compared to $22.0 million in the prior year period. The company completed dosing of all 25 participants in its Embolden registrational trial for NGN-401 and initiated Process Performance Qualification runs expected by year-end 2026. Long-term Phase 1/2 data showed 100% of participants improved on the CGI-I scale, gaining an average of 4.7 developmental milestones with no plateau observed through 30 months. Neurogene also executed an oversubscribed public offering generating approximately $144 million in gross proceeds, extending its cash runway into the first quarter of 2029. The company operates as a clinical-stage biotechnology firm developing genetic medicines for rare neurological diseases.

Neurogene Inc. entered into an underwriting agreement on June 30, 2026, to issue and sell 3,500,000 shares of common stock at $30.00 per share and pre-funded warrants to purchase up to 666,666 shares at $29.999999 per warrant. Underwriters exercised their option to purchase an additional 624,999 shares. Net proceeds are expected to be approximately $134.8 million. Neurogene Inc. is a biotechnology company focused on gene therapy development.

Neurogene Inc. announced on June 29, 2026, positive, updated clinical data from its Phase 1/2 trial evaluating NGN-401 gene therapy for the treatment of females with Rett syndrome. The company will host a conference call and webcast to discuss the results. Neurogene Inc. is a biotechnology company focused on developing gene therapies for neurodevelopmental disorders.

Neurogene Inc. announced the completion of dosing in its Embolden TM registrational trial of NGN-401 for the treatment of Rett syndrome on June 8, 2026. The company also updated its corporate presentation on its website.